Titan Pharmaceuticals Inc. reported a net loss of $689,000 for its second quarter on August 14, 2025. The New York-based company announced a loss of 65 cents per share for the period. These results reflect the company's financial performance during its ongoing strategic transition.
The reported loss is consistent with the company's minimal operational activity following the divestiture of its core ProNeura assets. This financial update provides investors with insight into the company's burn rate as it awaits the completion of its proposed business combination.
The continued reporting of net losses underscores the importance of the planned reverse merger with TalenTec Sdn. Bhd. for Titan's future financial stability. The company's focus remains on executing this strategic pivot and managing its limited cash resources.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.